Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA™ (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor (SNRI), discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults.